Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

The European Medicines Agency issued a positive opinion in December for the approval of Omvoh for moderately to severely active Crohn's disease. More on Eli Lilly Eli Lilly Q4: Don't Miss Out On ...

Lilly (NYSE:LLY) has submitted marketing applications for Omvoh for Crohn's disease worldwide, including the European Union and Japan. The product is approved for the treatment of ulcerative ...

2 1. FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease. News release. Eli Lilly and Company.

A breakdown of Crohn’s disease, its symptoms, causes, and long-term impact on health. Explore the causes, symptoms, diagnosis ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Crohn's disease, also known as ...

Omvoh has been cleared on the strength of ... but recently scored a win in a phase 3 Crohn’s disease study and, if approved in that indication, analysts have suggested it could eventually ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through ...